FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W611389716> ?p ?o ?g. }

• W611389716 endingPage "516" @default.
• W611389716 startingPage "512" @default.
• W611389716 abstract "CASE PRESENTATION “Mr. K,” a 52-year-old single Caucasian man, was diagnosedwith hepatitis C virus (HCV) infection nearly two decades ago after routine testing revealed an elevated alanine transaminase (ALT) level. Additional blood work identified an HCV genotype 1 infection with a viral load of 5.2310 IU/mL. While liver biopsy demonstrated cirrhosis, esophagogastroduodenoscopy showed no varices, and ultrasonography of the liver showed nodularity but no hepatocellular carcinoma. The patient’s only risk factor for HCV infection was a 1-month period of injection drug use (cocaine) 15 years earlier. Mr. K’s psychiatric history was significant for a major depressive episode with psychotic features requiring hospitalization, 6 years before the HCV diagnosis. He had a history of alcohol dependence, consuming up to 75 drinks/week episodically over the 20 years preceding the HCV diagnosis. At the time of his admission fordepression,hehadnotusedalcohol for3months.For the next 6 years, hewas treatedwith an antidepressant, at times in combinationwith an antipsychotic. After his diagnosis of HCV infection, he achieved abstinence from alcohol and was treated with citalopram (30 mg/day). Three years after theHCV diagnosis,Mr. K started weekly pegylatedinterferonalfa-2B(IFN-a2B)injectionsanddailyoral ribavirin forHCVinfection.After the initial IFN-a injection,he experienced significant sideeffects, includingexcessive fatigue, nausea, fevers, and worsening mood symptoms. He decided to take his ribavirin every other day without notifying his care team. At week 6, his HCV therapy was stopped because of delirium caused by the interferon. After a brief hospital admission, his mental status returned to baseline and he was discharged,withoutmodificationofhispsychiatricmedication. For the next 10 years, Mr. K was followed regularly for HCV infection by a hepatologist. Treatment was deferred because of the hepatologist’s concerns about psychiatric side effects. After 10 years, Mr. K developed mild ascites, which was controlledwithdiuretics. At that time, his liver enzymes remained elevated and his liver function had declined. After attending a collaborative-care hepatology and psychiatry clinic,hewasreassessed for interferon-basedtherapy.The clinic psychiatrist monitored Mr. K closely as IFN-a was initiated. Mr. K was started on boceprevir, pegylated IFNa2A, and ribavirin, with the aim of completing 48 weeks of treatment. At week 2, he complained of fatigue and poor sleep, and mirtazapine (15 mg/day) was used to augment the citalopram. Despite attempts to further optimize the citalopram and mirtazapine dosages, Mr. K’s fatigue worsened.Atweek22,hedeveloped liver failure andpresented to the emergency department with hepatic encephalopathy. HCV therapy was stopped and the patient’s mental status soon returned to baseline and his liver function improved. For the next 3 years, Mr. K remained stable with early liver failure. Then, on the eveningnews, heheard about new treatments forHCVinfection thatdonot require IFN-a, and he asked his psychiatrist and hepatologist about them. Simeprevir/sofosbuvir therapy was started, with a planned treatment duration of 12 weeks. Mr. K experienced mild nausea but no other side effects. Hewas followedweekly to monitorandencourageadherence to thisonce-daily two-pill regimen.Hecompleted the full course andwasconfirmed to have sustained virological response. No adjustments to his psychiatric medications were needed, and his depressive symptoms remained stable throughout his treatment." @default.
• W611389716 created "2016-06-24" @default.
• W611389716 creator A5020823849 @default.
• W611389716 creator A5030568929 @default.
• W611389716 creator A5049864482 @default.
• W611389716 creator A5056129100 @default.
• W611389716 date "2015-06-01" @default.
• W611389716 modified "2023-10-18" @default.
• W611389716 title "Psychiatric Care During Hepatitis C Treatment: The Changing Role of Psychiatrists in the Era of Direct-Acting Antivirals" @default.
• W611389716 cites W1973760746 @default.
• W611389716 cites W1977300462 @default.
• W611389716 cites W1979129700 @default.
• W611389716 cites W1992690275 @default.
• W611389716 cites W2007312063 @default.
• W611389716 cites W2019262762 @default.
• W611389716 cites W2035906120 @default.
• W611389716 cites W2038764499 @default.
• W611389716 cites W2043193067 @default.
• W611389716 cites W2056949851 @default.
• W611389716 cites W2061585427 @default.
• W611389716 cites W2078251659 @default.
• W611389716 cites W2081569952 @default.
• W611389716 cites W2089465091 @default.
• W611389716 cites W2092646281 @default.
• W611389716 cites W2107512529 @default.
• W611389716 cites W2120733999 @default.
• W611389716 cites W2127189337 @default.
• W611389716 cites W2143244227 @default.
• W611389716 cites W2150652264 @default.
• W611389716 cites W2151693584 @default.
• W611389716 cites W2154881336 @default.
• W611389716 cites W2160957455 @default.
• W611389716 cites W2162712320 @default.
• W611389716 cites W2164466220 @default.
• W611389716 cites W2171987406 @default.
• W611389716 cites W2314729165 @default.
• W611389716 doi "https://doi.org/10.1176/appi.ajp.2015.14081041" @default.
• W611389716 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26029803" @default.
• W611389716 hasPublicationYear "2015" @default.
• W611389716 type Work @default.
• W611389716 sameAs 611389716 @default.
• W611389716 citedByCount "14" @default.
• W611389716 countsByYear W6113897162015 @default.
• W611389716 countsByYear W6113897162017 @default.
• W611389716 countsByYear W6113897162018 @default.
• W611389716 countsByYear W6113897162019 @default.
• W611389716 countsByYear W6113897162020 @default.
• W611389716 countsByYear W6113897162021 @default.
• W611389716 countsByYear W6113897162022 @default.
• W611389716 countsByYear W6113897162023 @default.
• W611389716 crossrefType "journal-article" @default.
• W611389716 hasAuthorship W611389716A5020823849 @default.
• W611389716 hasAuthorship W611389716A5030568929 @default.
• W611389716 hasAuthorship W611389716A5049864482 @default.
• W611389716 hasAuthorship W611389716A5056129100 @default.
• W611389716 hasConcept C118552586 @default.
• W611389716 hasConcept C15744967 @default.
• W611389716 hasConcept C159047783 @default.
• W611389716 hasConcept C2776455275 @default.
• W611389716 hasConcept C71924100 @default.
• W611389716 hasConceptScore W611389716C118552586 @default.
• W611389716 hasConceptScore W611389716C15744967 @default.
• W611389716 hasConceptScore W611389716C159047783 @default.
• W611389716 hasConceptScore W611389716C2776455275 @default.
• W611389716 hasConceptScore W611389716C71924100 @default.
• W611389716 hasIssue "6" @default.
• W611389716 hasLocation W6113897161 @default.
• W611389716 hasLocation W6113897162 @default.
• W611389716 hasOpenAccess W611389716 @default.
• W611389716 hasPrimaryLocation W6113897161 @default.
• W611389716 hasRelatedWork W1886858294 @default.
• W611389716 hasRelatedWork W2022520514 @default.
• W611389716 hasRelatedWork W2027920975 @default.
• W611389716 hasRelatedWork W2074424214 @default.
• W611389716 hasRelatedWork W2155867731 @default.
• W611389716 hasRelatedWork W2170439237 @default.
• W611389716 hasRelatedWork W2620267228 @default.
• W611389716 hasRelatedWork W2748952813 @default.
• W611389716 hasRelatedWork W2769440133 @default.
• W611389716 hasRelatedWork W2899084033 @default.
• W611389716 hasVolume "172" @default.
• W611389716 isParatext "false" @default.
• W611389716 isRetracted "false" @default.
• W611389716 magId "611389716" @default.
• W611389716 workType "article" @default.